Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 52.02M
-1.78%-1.68%+1.99%+13.84% 48.42B
+0.85%-0.70%+465.55%+579.03% 43.66B
-2.40%-0.23%+12.20%+70.22% 39.51B
-2.01%-0.85%+24.95%+7.51% 38.95B
-0.50%+0.85%+20.60%+49.65% 32.61B
-0.59%-2.06%+26.13%+117.79% 16.15B
+0.38%-3.23% - - 16.32B
+0.49%+0.92%+4.32%+22.16% 14.16B
-0.43%+4.70%+79.75%+29.11% 13.37B
Average -0.60%+0.49%+79.44%+111.17% 29.24B
Weighted average by Cap. -0.91%+0.59%+97.63%+134.68%
Logo GenKyoTex SA
GenKyoTex SA is a France-based company involved in the biotechnology sector. The Company focuses on the development of therapies based on selective inhibition of nicotinamide adenine dinucleotide phosphate oxidase (NOX) enzymes, which cause a range of disease processes, such as fibrosis, inflammation, pain processing, cancer development and neurodegeneration. The Company's pipeline includes GKT831, a NOX inhibitor aimed at primary biliary cholangitis (PBC) and fibrosis; GKT771, a NOX inhibitor mainly aimed at inflammatory pain and angiogenesis, and other NOX inhibitors, which target at central nervous system (CNS), hearing loss and oncology.
Employees
-